Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William T Barry

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L Telli, Kirsten M Timms, Julia Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSara M Tolaney, Hao Guo, Sonia Pernas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative ChemotherapyAdrienne G Waks, Daniel G Stover, Jennifer L Guerriero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Genomic Characterization of <i>de novo</i> Metastatic Breast CancerAna C Garrido-Castro, Liam F Spurr, Melissa E Hughes, et al.
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Journal of the National Cancer Institute|August 10, 2020
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line ChemotherapyMark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, et al.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
JCI Insight|November 25, 2025
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Medrxiv : the Preprint Server for Health Sciences|April 8, 2025
Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled TrialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L Telli, Kirsten M Timms, Julia Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSara M Tolaney, Hao Guo, Sonia Pernas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative ChemotherapyAdrienne G Waks, Daniel G Stover, Jennifer L Guerriero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Genomic Characterization of <i>de novo</i> Metastatic Breast CancerAna C Garrido-Castro, Liam F Spurr, Melissa E Hughes, et al.
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Journal of the National Cancer Institute|August 10, 2020
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line ChemotherapyMark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, et al.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
JCI Insight|November 25, 2025
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Medrxiv : the Preprint Server for Health Sciences|April 8, 2025
Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled TrialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Pageof 13